BioNTech SE (BioNTech SE) Interest Income

: $459 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. BioNTech SE's interest income for the three months ended in Dec. 2023 was $131 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2023 was $459 Mil.

BioNTech SE Interest Income Historical Data

The historical data trend for BioNTech SE's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Income

Get a 7-Day Free Trial

2.00

1.95

1.70

51.38

389.97

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Income	Get a 7-Day Free Trial															41.10	64.35	165.11	98.72	131.30

BioNTech SE Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $459 Mil.

BioNTech SE (BioNTech SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.